PharmaceuticalsHealthcare & Drugs

GST on Pharma & Drugs — Medicines 5-12%, API 18%, Devices 5-18%

Complete GST guide for pharmaceutical industry: NLEM essential medicines (5%), branded formulations (12%), Active Pharmaceutical Ingredients (18%), vaccines (5%), medical devices (5-18%), Ayurvedic/AYUSH medicines (12%), inverted duty refund for manufacturers, online pharmacy TCS, clinical trials R&D, and hospital supply chain compliance.

5%

Essential Medicines

0% / 5%

Life-saving Drugs

12%

General Medicines

18%

OTC/Cosmeceuticals

12%

Medical Devices

18%

API/Bulk Drugs

5%

Vaccines

12%

Ayurvedic/Homeopathy

Pharma & Drugs — GST Framework

Essential Medicines — 5% GST (NLEM Listed)

National List of Essential Medicines (NLEM) drugs: 5% GST. NLEM 2022 covers 384 drugs across 27 therapeutic categories. Paracetamol (all formulations): 5%. Amoxicillin: 5%. Metformin (diabetes): 5%. Atorvastatin (cholesterol): 5%. Amlodipine (blood pressure): 5%. Omeprazole (acid reflux): 5%. Insulin (all types — human, analogue): 5%. Anti-TB drugs (DOTS regimen): 5%. Anti-malarial (chloroquine, artemisinin): 5%. Iron/folic acid supplements: 5%. ORS (Oral Rehydration Salts): 5%. Vaccines (all): 5% (HSN 3002). Blood and blood components: EXEMPT (0%). Human blood: exempt. Blood plasma: exempt. Blood bags: 5%. PRICING: DPCO (Drug Price Control Order) controls MRP of NLEM drugs. GST is INCLUDED in controlled ceiling price — pharma companies cannot charge GST OVER ceiling price. Trade margin: retailers get 16-20% on NLEM drugs (squeezed margins). Distributors: 8-10% margin. ITC: Pharma manufacturers claim ITC on API (18%), packaging (18%), machinery (18%) against 5% output — INVERTED DUTY STRUCTURE. Refund available under Section 54(3)(ii).

General Pharmaceuticals — 12% GST

Most formulations NOT in NLEM: 12% GST (HSN 3003/3004). This covers majority of branded prescription drugs. Branded generics (Dolo-650, Crocin, Combiflam): 12%. Antibiotics (branded — Augmentin, Azithral): 12%. Cardiac drugs (branded — Ecosprin, Telma): 12%. Anti-diabetic (branded — Glycomet, Januvia): 12%. Dermatology (creams, ointments): 12%. Ophthalmology (eye drops): 12%. Pain management (branded NSAIDs): 12%. Cough syrups: 12%. Antihistamines: 12%. Vitamins/supplements (therapeutic): 12%. Probiotics (pharmaceutical): 12%. Hormonal drugs: 12%. Oncology drugs (cancer — chemotherapy): 12%. Biologics/biosimilars: 12%. Surgical sutures: 12%. Surgical dressings/bandages: 12%. DISTINCTION FROM 5%: same molecule may be 5% (NLEM generic) or 12% (branded non-NLEM). Example: Paracetamol 500mg (generic) = 5%. Paracetamol 650mg (Dolo-650, not in NLEM formulation list) = 12%. This creates classification disputes — companies argue their formulation matches NLEM entry.

API & Bulk Drugs — 18% GST

Active Pharmaceutical Ingredients (API): 18% GST (HSN 2933-2942). Bulk drugs (raw material for formulation): 18%. Drug intermediates: 18%. Chemical compounds for pharma use: 18%. KEY APIs AND THEIR GST: Paracetamol API: 18% (but formulation: 5%). Ibuprofen API: 18%. Metformin API: 18%. Amoxicillin trihydrate API: 18%. Ciprofloxacin API: 18%. Atorvastatin calcium API: 18%. INVERTED DUTY PROBLEM (CRITICAL FOR PHARMA): Input (API): 18% GST. Output (formulation): 5% or 12% GST. Result: MASSIVE ITC accumulation. Example: ₹100 crore API purchase → ₹18 crore input GST. ₹200 crore formulation sale at 5% → ₹10 crore output GST. Accumulated ITC: ₹8 crore/year. Refund: file under Section 54(3)(ii). REALITY: refund processing takes 60-180 days, blocking working capital. CHINA DEPENDENCY: India imports 68% of API from China. Import: 18% IGST + customs duty (BCD 0-10% depending on API). PLI Scheme (Production Linked Incentive): government promoting domestic API — PLI incentive 5-20% of incremental sales. GST on PLI subsidy: NOT taxable (government grant, not consideration for supply).

Medical Devices & Equipment — 5-18%

MEDICAL DEVICES (post-2020 rationalization): Stents (coronary): 5% (was 12%, reduced after public outcry). Knee implants: 5%. Hip implants: 5%. Pacemakers: 5%. Cochlear implants: 5%. Intraocular lenses: 12%. Hearing aids: 5%. Wheelchairs: 5%. Artificial limbs/prosthetics: 5%. Crutches/walkers: 5%. Blood glucose monitors: 12%. BP monitors: 18%. Thermometers (digital): 18%. Syringes/needles: 5% (12% if disposable non-medical). Surgical instruments: 12%. X-ray machines: 18%. MRI/CT machines: 18%. Ultrasound machines: 18%. Ventilators: 12%. Oxygen concentrators: 12% (reduced from 28% during COVID). Hospital beds (motorized): 18%. Dental equipment: 18%. Lab equipment (microscopes, centrifuges): 18%. COVID IMPACT: Oxygen concentrators temporarily reduced to 12% (from 28%). COVID testing kits: 5% (temporarily). COVID vaccines: 5%. Pulse oximeters: 18% (no reduction despite demand). IMPORT: Most advanced medical devices imported — 18% IGST + customs BCD (0-15%). Government promoting 'Make in India' for medtech — customs exemptions on components for domestic manufacturing.

Ayurveda, Homeopathy & Traditional Medicine — 12%

AYUSH (Ayurveda, Yoga, Unani, Siddha, Homeopathy): Ayurvedic medicines (classical formulations): 12% (HSN 3003/3004). Proprietary Ayurvedic medicines: 12%. Homeopathic medicines: 12%. Unani medicines: 12%. Siddha medicines: 12%. NUTRACEUTICALS vs MEDICINES: If registered as 'Ayurvedic medicine' with AYUSH license: 12%. If marketed as 'food supplement' (FSSAI license): 18% (classified as food preparation). If marketed as 'cosmetic' (Ayurvedic cosmetic): 18-28%. CRITICAL CLASSIFICATION ISSUE: Chyawanprash — 12% (Ayurvedic medicine). Protein powder (Ayurvedic): 18% (if food supplement) or 12% (if medicine). Hair oil (Ayurvedic — Kesh King): if medicinal claim → 12%, if cosmetic → 28%. Pain balm (Zandu, Amrutanjan): 12% (medicine). Herbal tea (medicinal): 12% if medicine, 5% if tea. Aloe vera juice: 12% (if medicine) or 18% (if beverage). PATANJALI CASES: Multiple AAR (Advance Ruling Authority) cases on Patanjali products — conflicting rulings across states. Coronil (COVID): ruled as 'immunity booster' (food supplement) = 18%, not Ayurvedic medicine (12%). This classification battle affects ENTIRE Ayurveda/herbal industry — same product can have different GST depending on licensing and marketing claims.

Pharma Distribution & Hospital Supplies

DISTRIBUTION CHAIN GST FLOW: Manufacturer → C&F Agent → Distributor → Retailer → Patient. Each stage charges GST: Manufacturer sells to distributor: 12% on MRP minus trade margin. Distributor to retailer: 12% on further reduced price. Retailer to consumer: 12% on MRP (inclusive). All intermediaries claim ITC — revenue neutral in chain. HOSPITAL PHARMACY: Hospital buying medicines for in-patient use: composite supply. If hospital charges 'room + medicine + treatment' as package: GST on total package (healthcare exemption may apply). Healthcare services: EXEMPT from GST. But: medicines sold separately by hospital pharmacy to outpatients: 12% (supply of goods). GREY AREA: Is hospital medicine supply part of exempt healthcare? AAR rulings: if inseparable from treatment → exempt. If sold OTC from hospital pharmacy counter → taxable. PHARMA MARKETING: Free samples to doctors: no GST (no consideration). But ITC on manufacturing samples: blocked under Section 17(5)(h) — gifts/free samples. Doctor incentives (gifts, conferences): not taxable to doctor. Pharma company: ITC blocked on such expenses. TRADE DISCOUNTS: Discount on invoice (quantity discount): GST on net amount (reduced). Post-supply discount (year-end rebate): credit note with GST adjustment. Free goods scheme ('buy 10, get 2 free'): GST on total value INCLUSIVE of free goods (ITC reversal issues).

Pharma & Drugs — GST Rate Table

ItemHSN/SACGST RateNotes
Life-saving drugs (blood, organs)3001/30020% ExemptHuman blood, vaccines (some)
NLEM essential medicines3003/30045%384 drugs, price-controlled
Vaccines (all types)30025%Including COVID vaccines
Insulin (all formulations)30045%Human + analogue
Branded formulations (non-NLEM)3003/300412%Most prescription drugs
Ayurvedic/Homeopathic medicines3003/300412%Licensed AYUSH products
Active Pharma Ingredients (API)2933-294218%Bulk drug raw materials
Nutraceuticals/food supplements210618%FSSAI-licensed products
Stents/implants (coronary, knee)90215%Life-saving implants
Surgical instruments901812%Scalpels, forceps, etc.
Diagnostic equipment (MRI, CT)901818%Imaging machines
Oxygen concentrators901912%Reduced post-COVID

Frequently Asked Questions

Why does the same medicine (e.g. Paracetamol) attract 5% in one formulation but 12% in another?
GST rate depends on whether the SPECIFIC formulation is listed in the NLEM (National List of Essential Medicines). NLEM lists drugs by: molecule name + strength + dosage form. Paracetamol 500mg tablet: IN NLEM → 5% GST. Paracetamol 650mg tablet (Dolo-650): NOT in NLEM (specific 650mg strength not listed) → 12% GST. Paracetamol 1000mg tablet: NOT in NLEM → 12%. Paracetamol + Caffeine combination (Saridon): NOT in NLEM (combination not listed) → 12%. WHY THIS MATTERS: same API (paracetamol), different GST rate based on exact formulation match with NLEM. DISPUTES: Companies argue their formulation is 'essentially' the same as NLEM entry. Revenue department says: must be EXACT match (molecule + strength + form). Courts: mixed rulings — some allow 5% for 'substantially similar' formulations. PRACTICAL IMPACT: MRP of NLEM drug (5% GST) is lower → affordability focus. Non-NLEM branded version (12% GST) has higher MRP → better margins for company. Pharmacists: must verify NLEM status for each drug to apply correct GST. Software systems: need updated NLEM database mapped to GST rates.
How does inverted duty structure affect pharma manufacturers and what refund is available?
INVERTED DUTY IN PHARMA: Input (API/bulk drug): 18% GST. Output (formulated medicine): 5% or 12% GST. Difference: 6-13 percentage points of trapped ITC every month. SCALE OF PROBLEM: India's pharma market: ₹2 lakh crore (USD 25 billion). Estimated annual ITC accumulation (industry): ₹8,000-12,000 crore. Individual large company (Sun Pharma, Cipla): ₹200-500 crore/year accumulated ITC. REFUND MECHANISM: Section 54(3)(ii) CGST Act: 'refund of ITC where credit accumulates due to inverted duty structure.' Formula: Maximum refund = (Turnover of inverted supply ÷ Adjusted total turnover) × Net ITC − Output tax on inverted supply. File: Form RFD-01 (monthly/quarterly). Timeline: 60 days (statutory) — practical: 90-180 days. LIMITATIONS: (a) Refund only on INPUT GOODS — not input services (Supreme Court ruling in VKC Footwear case). So: ITC on contract manufacturing service (18%), R&D services (18%), logistics (18%) — NO REFUND. Only ITC on physical inputs (API, packaging material, excipients) eligible for refund. (b) Capital goods ITC: NOT eligible for inverted duty refund. ₹500 crore pharma plant machinery ITC: must be absorbed against output tax over time — cannot claim refund. INDUSTRY DEMAND: reduce API to 12% (from 18%) to narrow inversion. Government reluctant: API is also a finished product (exported) — revenue implications.
What GST applies to clinical trials, R&D services, and drug discovery in India?
CLINICAL TRIALS (Contract Research — CRO services): Conducting clinical trials for pharma companies: 18% GST (SAC 9983 — R&D services). Bio-equivalence studies: 18%. Pharmacovigilance services: 18%. Regulatory filing services (CDSCO, FDA): 18%. Clinical data management: 18%. IF EXPORTED (Indian CRO doing trials for foreign pharma): Zero-rated. Many Indian CROs (Syngene, Lambda Therapeutic) do trials for US/EU pharma → export of service → 0% with LUT. R&D SERVICES: Drug discovery research: 18%. Molecular synthesis: 18%. Formulation development: 18%. Analytical testing (stability, dissolution): 18%. Bioanalytical services: 18%. PATENT/IP: Filing patent (legal services): 18%. Patent licensing royalty (from foreign company to Indian licensee): 18% under RCM (import of service). Compulsory license (government-issued): royalty still taxable at 18%. ACADEMIC RESEARCH: University/IIT conducting pharma research: if under grant (no consideration): not taxable. If contract research for pharma company: 18% (even by educational institution — research is not 'education'). SPECIAL ECONOMIC ZONE (SEZ): Pharma company in SEZ doing R&D: zero-rated supplies to DTA (Domestic Tariff Area). API manufactured in SEZ for domestic market: IGST applicable when cleared from SEZ to DTA.
How does GST work for online pharmacy platforms (PharmEasy, 1mg, Netmeds)?
ONLINE PHARMACY GST: E-commerce operator (PharmEasy, Tata 1mg, Apollo 24|7): Platform sells medicines to consumers. GST on medicine: 5% or 12% (depending on NLEM status) — same as offline pharmacy. TCS (Tax Collected at Source): E-commerce operator MUST deduct 1% TCS (0.5% CGST + 0.5% SGST) on net taxable value of supplies made through platform. File GSTR-8 monthly. Example: Medicine sold ₹1,000 (12% GST). Platform collects ₹1,120 from customer. TCS: 1% of ₹1,000 = ₹10 deducted from seller's payment. Seller receives ₹1,110 (₹1,120 − ₹10 TCS). Seller claims TCS credit in their GSTR-3B. MARKETPLACE vs INVENTORY MODEL: Marketplace (most platforms): Platform connects buyer-seller. GST charged BY seller (individual pharmacy). Platform charges commission: 18% GST on commission. Inventory model (platform owns stock): Platform IS the seller. Platform charges GST directly on medicine. Platform claims ITC on purchase from manufacturer/distributor. DELIVERY CHARGES: Delivery fee charged to customer: 18% GST (transportation service). If 'free delivery' (absorbed by platform): no separate GST — included in composite supply. DISCOUNT: Platform discount (funded by platform): no GST adjustment — platform bears cost. Seller discount (funded by manufacturer): credit note mechanism — GST adjusted. PRESCRIPTION REQUIREMENT: Online pharmacies MUST verify prescription for Schedule H/H1 drugs. No GST implication — but regulatory compliance needed for valid sale.

Pharma GST — Multi-Rate Billing, Inverted Duty Refund, NLEM Compliance

Laabam.One handles pharma industry GST: 5%/12%/18% multi-rate drug classification, NLEM-linked auto-rate detection, inverted duty ITC refund computation, online pharmacy TCS deduction, medical device categorization, and AYUSH medicine compliance.

Explore GST Law